Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants
Joseph R. Shaw, Director of Research Plus Program at Ottawa Department of Medicine, EHJ-CVP Associate Editor at European Heart Journal, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Pharmacology and Therapeutics, adding:
”I am very happy to share our new review, ‘Thrombin generation and the pharmacodynamics of oral anticoagulants,’ published in Pharmacology and Therapeutics-one of the ten most-cited journals in pharmacology.
From a pharmacodynamic perspective, not all anticoagulants are the same. Drug levels and conventional clotting assays are useful, but do not fully describe how anticoagulants differentially impact thrombin generation.
Blocking coagulation factors near coagulation’s fulcrum, particularly prothrombinase or thrombin, is less susceptible to redundancy. Multitarget inhibition, on the other hand, disrupts the entire system. Pharmacodynamic potency therefore reflects not only binding affinity or reversibility for a primary target, but also its positional leverage within the network and the number of convergent points it engages.
We use thrombin generation as a common language for comparative anticoagulant pharmacology. Broader-acting agents such as VKAs and UFH achieve deeper, cumulative suppression. The tradeoff familiar to clinicians is pharmacokinetic fragility and, on average, less consistency. Direct inhibitors provide greater pharmacodynamic consistency despite increasingly recognized variability in drug levels within and between patients.
These differences may help explain why broader-acting anticoagulants better preserve antithrombotic efficacy in highly prothrombotic settings, mechanical heart valves, antiphospholipid syndrome, rheumatic mitral stenosis, and catheter-associated thrombosis. The same deeper suppression may also help explain the higher intracranial hemorrhage risk with VKAs versus DOACs.
These signatures may help model molecular pharmacology’s effects on coagulation and better account for pharmacological contributions to bleeding and breakthrough thrombosis, even when drug concentrations appear ‘on target.’
The review builds on and expands the framework we recently proposed for parenteral anticoagulants in Pharmacological Reviews.
We extend this framework across oral classes, with implications for how we perceive anticoagulants and how factor XI inhibitors fit within the current therapeutic landscape.
We hope it will be a useful reference for comparative anticoagulant pharmacology over the next decade.”
Title: Thrombin generation and the pharmacodynamics of oral anticoagulants
Authors: Joseph R. Shaw, Cheryl L. Maier, Michael Hardy, François Mullier, Jonathan Douxfils, Kenichi Tanaka, Bianca Rocca, Hugo ten Cate, Paul Y. Kim, Marc Carrier, Jean M. Connors, Jerrold H. Levy
Find more posts featuring Joseph R. Shaw on Hemostasis Today.
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs